Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Pfizer110 enrolled

Overview

The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

110

Conditions

Growth Disorders

Interventions

GenotropinDRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 7 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Birth length below -2 SD * Height at start below - 2 Sd Exclusion Criteria: * Any endocrine or chronic disease * Any known syndrome with short stature

Outcomes

Primary Outcomes

Height, height velocity

Secondary Outcomes

Side effects

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.